Why Wegovy (semaglutide 2.4 mg) Causes Vomiting: The Mechanism Explained

What the label records about vomiting on Wegovy

The Wegovy label pools three placebo-controlled trials in adults with obesity or overweight: 2,116 people took semaglutide 2.4 mg once weekly for up to 68 weeks and 1,261 took placebo [1]. Vomiting occurred in 24% versus 6%. Nausea occurred in 44% versus 16%, diarrhea in 30% versus 16%, constipation in 24% versus 11%, and abdominal pain in 20% versus 10% [1]. Any gastrointestinal reaction was reported by 73% versus 47% [1].

In those trials 6.8% of people on semaglutide and 3.2% on placebo stopped treatment permanently because of adverse reactions, and vomiting was the stated reason for 1.2% versus 0% [1]. The label also carries a separate warning for severe gastrointestinal reactions: 4.1% versus 0.9% in the injection trials, and 2% versus 0% in the 25 mg tablet trial [1]. In STEP 1, 4.5% of semaglutide participants and 0.8% of placebo participants discontinued for gastrointestinal events [2].

Action one: semaglutide delays gastric emptying

The label states that semaglutide delays gastric emptying, and its drug interaction section notes that this gives the drug the potential to affect how oral medicines are absorbed [1].

The label's handling of this effect is visible in two places. First, it says Wegovy is not recommended in patients with severe gastroparesis, a condition of delayed stomach emptying [1]. Second, postmarketing reports for the drug include ileus, intestinal obstruction and severe constipation with fecal impaction; the label says frequency cannot be estimated from voluntary reports [1].

Action two: GLP-1 receptors in the brain

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake [1]. The label does not say how much either this action or delayed gastric emptying contributes to vomiting [1].

How the dose ladder relates to vomiting

Wegovy is started at 0.25 mg weekly for 4 weeks, then raised every 4 weeks through 0.5 mg, 1 mg and 1.7 mg to a maintenance dose of 2.4 mg from week 17. The label says this escalation is intended to minimize gastrointestinal adverse reactions [1]. In the label's weight-management trials vomiting was more frequent on 7.2 mg than on 2.4 mg, and more frequent on 2.4 mg than on placebo [1]. In two 72-week trials with 1,311 adults on 7.2 mg, 304 on 2.4 mg and 303 on placebo, the rates were 22%, 16% and 6%, and gastrointestinal reasons led 3%, 3% and 0.3% to stop [1].

After a subcutaneous injection, semaglutide reaches peak blood levels 1 to 3 days later and has an elimination half-life of about a week. It remains in the body for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or 25 mg tablet [1].

Label warnings that involve vomiting or fluid loss

• Kidney injury from fluid loss. Acute kidney injury due to volume depletion occurred at 0.4 versus 0.2 cases per 100 patient-years in the Wegovy trials (7 versus 4 adults), more often in patients with prior renal impairment and during dose titration, and often after gastrointestinal fluid loss [1]. The label says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1].
• Pancreatitis. The label says to watch for acute pancreatitis, which may cause persistent or severe abdominal pain (sometimes radiating to the back) and may or may not be accompanied by nausea or vomiting; if pancreatitis is suspected, the label says to discontinue Wegovy and start appropriate management [1].